fbpx

YOUR GUIDE TO STAYING INFORMED IN THE MARKETS

Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

A Sprinkling Of Fed Worries/Global Growth Fears & Tax Loss Swaps Knocked Out Stocks This Week

By John F. Heerdink, Jr.
Quote of the Day:  “By three methods we may learn wisdom: First, by reflection, which is noblest; Second, by imitation, which is easiest; and third by experience, which is the bitterest.” – Confucius


Happy Saturday All!

I hope you all had an amazing week & that you have been able to enjoy the amazing knock out stage games of the 2022 World Cup. I like France to take it all as I have since the start, but Croatia has been solid and their win over Brazil was impressive. However, the beauty of Argentina’s Messi led team has been entertaining and they cannot be ruled out. Who do you happen to see winning this year? Congratulations also goes out to the USMNT who bowed out, but represented us all well, and I am excited to see how we progress in the years to come. I predict that many more of our US players will be in the top leagues around the world as we move forward as the flood gates are truly and widely open and that we will have an increased pool of very experienced and talented players to choose from when we compete at the world stage in four years. 

As for the markets this week we experienced a downward trend. Fueling the decline, at least in part, was macroeconomic schedule that produced another set of reports that unfortunately left many a bit confused if not pessimistic as to where the Fed’s head will be when they meet next week (Dec. 13-14) to reveal their latest interest rate decision. On Monday, the ISM Non-Manufacturing Index report for November showed a rise to 56.5%. The factory orders for manufactured goods report also confirmed a 1% M/M rise in October, while shipments of manufactured goods rose .7%. The final IHS Markit Services PMI report for November was confirmed to have edge marginally higher to 46.2. On Tuesday, the October Trade Balance report confirmed the deficit widened to $78.2B. On Wednesday, the Weekly MBA Mortgage Application Index report confirmed a 1.9% drop. The Nonfarm business sector labor productivity report showed a .8% rise in Q3, while the unit labor costs report shoed a 2.4% increase. The Consumer credit report confirmed $27B increase in October. The Weekly EIA Crude Oil Inventories report showed came in with 5.19M barrel draw. On Thursday, the initial claims report for the week ending December 3 showed a 4k rise to 230k, while the continuing claims report for the week ending November 26 confirmed a 62k increase to 1.671M. The Weekly EIA Natural Gas Inventories report also confirmed another 21 bcf draw. On Friday, the Producer Price Index report for final demand showed a .3% M/M rise in November & on a Y/Y basis it was up 7.4%. The Wholesale Inventories fell to 0.5% in October from a revised 0.8% in September (from 0.6%). The preliminary December University of Michigan Index report of Consumer Sentiment came in higher at 59.1. On Friday, the yield curve closed with the 2-yr note yield rising by 8 basis points to close at 4.361% & the 10-yr note yield moving up by 10 basis points to close at at 3.59%.

Global growth and/or recessionary worries fueled by supply constraint concerns and disruptions, rising prices, except for housing which is falling in many parts of the country, coupled with upward moving interest rates continued to grow in investors minds.  However, oil prices closed lower at $71.48/bbl and falling solid 1o.6% this week much to the chagrin of Putin and Co. & OPEC+, but a welcomed site at the local gas station as prices fell sharply and even in San Francisco we were able to fill up with premium for under $5/gallon once again and leaving a few extra dollar in the wallet. The US dollar also stabilized to a degree after its recent pullback edging slightly higher to close at $104.93.  

At the end of the week, the major indices closed significantly lower where growth oriented investments were definitively out of favor. The S&P 500 closed at 3,934 (-3.4%) for the week and is now down 17.5% YTD. 11 of the 11 sectors closed in the red with the energy sector taking the biggest hit legging down 8.4% as oil prices cratered. The communication services sector fell 5.4% & the consumer discretionary sectors falling 4.5% round out the top three heaviest hit sectors. The 6.82% weighting of Apple (AAPL) placed some decent pressure again this week closing at $142.16 moving down 3.82% over the last 5-days. The Dow 30 closed lower at 33,476 (-2.8%) and is down 7.9% YTD. The Nasdaq closed at 11,005 (-4%) for the week and is down 29.7% YTD. In line with the negative bias, the CBOE Volatility Index (^VIX) closed at $22.83, +19.78% over the last 5-days and remains up +32.58% YTD. The small caps on the Russell 2000 also got relatively hit and closed at 1,796.66 (5.08%)  & is now down 19.98% YTD. The MicroCaps joined the upward downward trajectory this week as the iShares Micro-Cap ETF (IWC) closed at $108.62, down 4.70% over the last 5-days and is now down 22.26% YTD. Tax swap or loss selling also added to the overall pressure and hopefully setting us for one heck of a January Effect trade. The January effect is a hypothesis that there is a seasonal anomaly in the financial market where securities’ prices increase in the month of January more than in any other month. This calendar effect would create an opportunity for investors to buy stocks for lower prices before January and sell them after their value increases. 

BIOTECH AND HEALTHCARE

Biotech stocks fell overall this week. The Nasdaq Biotechnology ETF (IBB) moved down and closed at $133.01, -3.92% over the last 5-days & is down 12.85 YTD. The NYSE ARCA Biotech Index (^BTK) closed at 5,219.13, -3.96% over the last 5-days and is now down 5.42% YTD. The SPDR S&P Biotech ETF (XBI) closed at $79.53, -7.16% over the last 5-days & is now down 28.97% YTD. The 52-week range is is now $61.78-$119.21.

The iShares U.S. Healthcare ETF (IYH) closed at $287.08, -1.41% over the last 5-days and is down -4.42% YTD.

EV, TECH, CONSUMER, FINANCIALS

Apple (AAPL) closed at $142.16, -3.28% over the last 5-days. Apple represents a 6.82% weighting in the S&P 500.  Reportedly, Amid supply chain difficulties stemming from China’s zero-COVID policy, Foxconn’s founder has urged some manner of ‘Chinese leaders’ to ease some of the country’s guidelines and apparently their may be progress. 

 

tesla

EV giant Tesla (TSLA) closed at $179.05, -8.11% over the last 5-days. Wedbush senior analyst Dan Ives told Yahoo Finance regarding COVID’s impact on automakers in China, “It has been a nightmare. I think you’re starting to see cracks in the armor for the first time in many years and obviously competition is increasing in the EV land, and I almost call it a ‘Game of Thrones’ going on between Tesla and others, and I think that’s the heart and lungs of the EV story — there is pressure on the automakers and it is a storm to navigate.”

On Dec. 1, Tesla revealed its Semi, a 18-wheeler long-haul electric freight hauler, which the first will roll out to PepsiCo. (PEP). The Semi has a 500-mile range while hauling 82k pounds of freight according to Tesla. 

 
 
Shares of ADT Inc. (ADT), the most trusted brand in smart home and small business security, closed at $9.64, -1.13% over the last 5-days, but established a new 52-wk high at $9.98 along the way. On Nov. 3, ADT, announced its results for the third quarter of 2022. They highlighted Total revenue of $1.6 billion, up 22% or 8% excluding Solar, and end-of-period Recurring Monthly Revenue (RMR) of $372 million, up 4%, Record high customer retention with gross customer revenue attrition at 12.6%, Record revenue payback of 2.1 years, & GAAP net loss of $122 million, or a loss of $(0.13) per diluted share, down $13 million. The board of ADT announced that it will pay a dividend of $.035.share on the 4th of January or 1.6% yield.
 
On Oct. 13, ADT, announced that it has issued and sold in a private placement to State Farm 133.3 million shares of ADT common stock for a gross purchase price of $1.2 billion. In September, ADT announced a new partnership with State Farm to revolutionize the homeownership experience through innovation in the detection and mitigation of property losses. In addition to the equity investment, State Farm has committed up to $300 million to fund product and technology innovation, customer growth and marketing activities in connection with the partnership. State Farm has funded the first $100 million and the two companies will collaborate to approve initiatives utilizing the funds.

Shares of JPMorgan (JPM) closed at $132.16, -2.22% over the last 5-days. On December 1, J.P. Morgan announced launched Wealth Plan today, a free digital money coach that gives clients a full picture of their finances and helps them plan, save and invest, all in one place. The experience will be available for free to all 62 million digitally-active Chase customers in the top-ranked Chase Mobile app and Chase.com.

Shares of Amazon.com, Inc. (AMZN) closed $89.09,-5.35% over the last 5-days.  On December 8, Amazon Games and Bandai Namco Online Inc. today announced they are bringing Blue Protocol, a multiplayer online action role-playing game featuring beautiful, anime-inspired art, to North America, Europe, South America, Australia, and New Zealand. Blue Protocol will be free-to-play, and will launch for PC, Xbox Series X|S, and PlayStation 5 in the second half of 2023, with a Closed Beta on PC earlier in the year. View the gameplay trailer, which debuted tonight at The Game Awards, here.


Shares of Microsoft Corp. (MSFT) closed at $245.42,-3.76% over the last 5-days. On Dec. 8, Microsoft received news that the FTC is seeking to possibly block its purchase of gaming company Activision Blizzard (ATVI, $75.16, +.54%).

Shares of Salesforce, Inc. (CRM) closed at $131.11, -9.30% over the last five days. On Nov. 30, Salesforce announced that Bret Taylor will step down as Vice Chair and Co-CEO of Salesforce, effective January 31, 2023, while Marc Benioff will be Chair and CEO of the company.

Shares of NVIDIA (NVDA), a pioneer in accelerated computing, closed at $170.01, +.74% over the last 5-days. On Dec. 7,  KULR Technology Group, Inc. ( KULR), a leading energy management platform company accelerating the global transition to a sustainable electrification economy, announced that it will be expanding its vibration reduction solution KULR VIBE offering with the launch of a scalable, centralized artificial intelligence (“AI”) server platform. Powered by NVIDIA accelerators, the updated KULR VIBE system will deliver faster processing speeds and data capture for remote access.

Cathie Wood’s ARK Innovation ETF (ARKK) closed at $34.65, -9.20% over the last 5-days. 

The Technology Select Sector SPDR Fund (XLK) closed at $130.91, -3.29% over the last 5-days. 

Shares of McDonald’s (MCD) closed at $272.04, -.50% over the last 5-days. On October 27, McDonald’s Corporation announced results for the third quarter ended September 30, 2022 and highlighted the following: 1) Global comparable sales increased nearly 10%, with growth across all segments, 2) U.S. comparable sales increased more than 6% for the quarter, marking the ninth consecutive quarter of comparable sales growth for the segment, & 3) Digital Systemwide sales* in our top six markets were nearly $7 billion for the quarter, representing over a third of total Systemwide sales in those markets.


GOLD & SILVER

Gold prices closed at $1804/oz., -$1/oz. & silver prices closed at $23.55/oz., +$.32/oz. for the week.

Hecla Mining (HL) closed at $5.55,-2.97% over the last 5-days & First Majestic (AG) closed at $8.91, -6.60% over the last 5-days. 


MEMES CENTRAL

AMC Entertainment (AMC) closed at $5.94, -27.79% & (APE) closed at $.7703, -22.66% over the last 5-days.  

GameStop (GME) closed at $22.63, -17.77% over the last 5-days as the shorts won solidly overall this week. Note that approx. 20% of GME’s outstanding shares are sold short landing it with a short interest ratio of 7.6. On Dec. 7, GME released financial results for the third quarter ended October 29, 2022 highlighting that Net sales were $1.186 billion, compared to $1.297 billion in the prior year’s third quarter & that Sales attributable to new and expanded brand relationships were strong in the quarter, while sales in the collectibles category remained strong on a year-to-date basis.

Seanergy Maritime Holdings Corp. (SHIP) closed at $.5171, -.56% over the last 5-days. On Dec. 9, Seanergy announced the filing of an amendment to its Schedule TO and Offer to Purchase (the “Amendment”), both dated as of November 30, 2022, relating to the Company’s tender offer to purchase all outstanding Class E common stock purchase warrants (the “Warrants”) at a purchase price of $0.20 per Warrant, which tender offer will expire at the end of day, 5:00 P.M., Eastern Time, on January 10, 2023, unless extended or withdrawn. The Company has filed the Amendment on Schedule TO and the Amendment may be accessed from the Securities and Exchange Commission’s website at www.sec.gov.

On Nov. 30 after the close, SHIP announced its financial results for the third quarter and nine months ended September 30, 2022. The Company also declared a quarterly dividend of $0.025 per share for the third quarter of 2022.



CRYPTO & BITCOIN

Bitcoin (BTC) closed at $17,129.34, up +.91% over the last 5-days at the time this report was prepared. 

ENERGY

The Energy Select Sector SPDR Fund or ETF (XLE) closed at $82.68, -8.45% over the last 5-days. Chevron (CVX) closed at $168.00, -7.20% over the last 5-days. Warren Buffet’s pick in the space, Occidental Petroleum (OXY) closed at $62.60, -8.22% over the last 5-days.

Oil prices closed on Friday to end at $71.48/bbl and down a solid 10.6% this week, leaving oil down 5% for the year.

NEXT WEEK



A full five action packed trading days are back on the agenda again next week along with the Fed’s next interest rate decision when they conclude their Dec. 13-14 FOMC meeting. 

VP WATCHLIST UPDATES

Please review a select group of emerging names below and their updates below:

  • Shares of Natural-Killer cell (NKcell) focused biopharmaceutical firm Fate Therapeutics (FATE) closed at $18.90, 9.61% over the last 5-days. 
    • November 3, Fate reported business highlights and financial results for the third quarter ended September 30, 2022 with  Cash, cash equivalents and investments as of September 30, 2022 were $519.1 million. Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics stated, “We are very pleased with the positive feedback from the FDA under our FT516 RMAT designation in support of our iPSC product platform and potential registrational pathways for the treatment of relapsed / refractory aggressive lymphomas, including for patients who have previously failed CD19-targeted CAR T-cell therapy, and we look forward to engaging the FDA in the fourth quarter to discuss CMC topics in support of pivotal trial readiness. We are also excited to present interim Phase 1 clinical data at the upcoming SITC and ASH conferences, including for our iPSC-derived CAR NK cell programs FT576 in multiple myeloma and FT536 in solid tumors as well as for the first-ever iPSC-derived CAR T-cell program FT819 in B-cell lymphoma. Finally, under our collaboration with Janssen, we are pleased to announce our first IND candidate FT555, a multiplexed-engineered, iPSC-derived CAR NK cell targeting GPRC5D for multiple myeloma, and that Janssen has also exercised its commercial option to an additional product candidate targeting an undisclosed hematologic malignancy antigen.”


  • Shares of Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need in oncology, with a current focus on breast cancer and radiation-induced lung injury, closed at $.6687. 
    • On Dec. 7, Atossa announced the appointment of Eric Van Zanten as Vice President of Investor and Public Relations. Mr. Van Zanten brings over 25 years of corporate communications experience working within the biopharmaceutical, finance, and healthcare industries. He will oversee corporate, executive, and digital communications, investor relations, thought leadership, and branding for the Company. Prior to joining Atossa, Mr. Van Zanten led corporate affairs at Faron Pharmaceuticals, a clinical stage biopharmaceutical company focused on tackling difficult-to-treat cancers via precision macrophage immunotherapy and Urogen Pharma, a commercial stage biotech delivering innovative solutions that treat specialty cancers. He was also formerly Head of Commercial and Medical Communications and Director of Oncology Communications at Bristol-Myers Squibb where he helped launch Opdivo, one of the most successful oncology brands ever. Earlier in his career he held communications leadership roles at Deloitte, Booz Allen & Hamilton, Children’s Hospital of Philadelphia and Unisys Corporation.“We are excited to welcome Eric to Atossa as we sharpen our focus on developing new therapies for cancer patients,” said Steven Quay, M.D., Ph.D., President and Chief Executive Officer of Atossa. “His extensive industry experience and oncology background make him particularly well-suited to help us share the Atossa story with investors, researchers, media, industry partners and other stakeholders.”
    •  
    • On Nov. 7, Atossa announced its financial results for the fiscal quarter ended September 30, 2022, and provided an update on recent company developments. Atossa is a clinical-stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology with a current focus on breast cancer and lung injury caused by cancer treatments. Key developments from Q3 2022 and to date included:

      • Received FDA authorization from FDA to initiate its Phase 2 study of neoadjuvant (Z)-endoxifen in premenopausal women with ER+/HER2- breast cancer.
      • Invested in a privately-held Dynamic Cell Therapies, a company focused on CAR-T therapies as an important step in pursuing its strategy to develop CAR-T therapies or adjacent opportunities within the immuno-oncology space.
      • Completed dosing in both Part B and Part C (of four parts) of Phase 1/2a Clinical Trial of AT-H201 in healthy volunteers, which the Company is now developing for patients with compromised lung function due to the damaging effects of cancer treatment.
    • On November 1, Atossa announced that it is investing in privately-held developer of CAR-T therapies, Dynamic Cell Therapies, Inc. (DCT), a venture capital backed company that is based in Boston, MA. DCT is in the pre-clinical phase of developing controllable CAR-T cells to address difficult-to-treat cancers. Its platform technology of dynamic control of engineered T-cells is designed to improve the safety, efficacy, and durability of CAR-T cell therapies. This system should find initial applications in hematological cancers, with future approaches in solid tumors and autoimmune diseases. The company’s platform technology uncouples tumor targeting from CAR-T cell activation. Each CAR-T cell recognizes an inert small molecule. This small molecule is conjugated to a tumor-specific antibody. By dosing a small molecule-antibody conjugate, the physician could dynamically control CAR-T cell activity and potentially minimize the risk of life-threatening side effects. Increasing the dose of the small molecule-antibody conjugate should strengthen the immune attack against tumor cells. In addition, the same small molecule can be coupled to different tumor targeting antibodies, allowing the physician to maximize on-target on-tumor efficacy and reduce off-tumor toxicities. To learn more, please visit www.dynamiccelltherapies.com. Steven Quay, M.D., Ph.D., Atossa’s CEO, Chairman and President stated, “This investment in DCT is an important step in pursuing our strategy to develop CAR-T therapies or adjacent opportunities within the immuno-oncology space. We believe that as an active investor in the development of DCT we will be well positioned to evaluate future opportunities while strategically managing our cash position.” Atossa will acquire shares equal to 19.99% of the outstanding capital stock of DCT as of today for a cash payment of $2 million (in addition to $3 million previously paid to DCT). The transaction is expected to close in the fourth quarter.
       
    • On October 25, Atossa announced that it has retained Richard Graydon, M.D., Ph.D. as interim chief medical officer. Dr. Graydon will devote all of his professional time to the Atossa clinical programs. Prior to joining Atossa, Dr. Graydon served as Senior Director of Clinical Development at Johnson and Johnson (JNJ) where he was responsible for leading compound development and clinical trial programs for Janssen Pharmaceuticals. At Janssen, he oversaw the early to late-stage development and the 2022 approval of BCMA-directed CAR T-Cell therapy (cilta-cel) for Multiple Myeloma, as well as daratumumab, imbruvica, siltuximab and other compounds for solid tumor and hematological malignancies. Previously, he held the role of Director of Clinical Development at Daiichi Sankyo, Inc., where he led the early and late-stage development of the small molecule targeted therapy quizartinib for FLT3-positive Acute Myeloid Leukemia. Additionally, he led the early-stage development of the MDM2 inhibitor milademetan in hematological malignancies and liposarcomas. Dr. Graydon spent time in clinical practice following completion of his specialty training in hematology and oncology at Harvard Massachusetts General Hospital. He earned his M.D. and Ph.D. at Stanford University, and undergraduate degree in Chemical Engineering at Cornell University. Dr. Graydon is the author of The Genetic Risks of Cancer: The Effects of DNA, Genomics and Inheritance on Aging and Survival.
    • On Oct. 24, Atossa announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold and authorized initiation of its Phase 2 neoadjuvant clinical study of (Z)-endoxifen in premenopausal women with early-stage estrogen receptor positive (ER+) and human epidermal growth factor receptor 2 negative (HER2-) breast cancer. This is the first study of Atossa’s proprietary (Z)-endoxifen in the United States. At this time, Atossa also announced that it is discontinuing its COVID-19 program (AT-301) so that it can refocus resources on this critical study in breast cancer. “Continuing the development of our proprietary (Z)-endoxifen here in the United States has been a key goal which builds on the recent issuance of a U.S. patent for our proprietary (Z)-endoxifen and results from our Phase 2 “window-of-opportunity” study in Australia,” commented Steven Quay, M.D., Ph.D., Atossa’s CEO, Chairman and President. “We are excited to have engaged Dr. Matthew Goetz, the Erivan K. Haub Family Professor of Cancer Research Honoring Richard F. Emslander, M.D. at Mayo Clinic and Director of the Mayo Clinic Breast Cancer SPORE, as the lead principal investigator for this multi-center study. We look forward to opening the study in the fourth quarter.”

  •  

  • The multi-billion-dollar global fertility market is predicted to reach approximately US$47.9 billion by 2030, yet remains severely underserved with many patients (upwards of 90% by many estimates) unable to access affordable treatment. INVO Bioscience, Inc. (NASDAQ: INVO) offers the INVOcell solution which provides an advanced, effective and affordable infertility treatment to help increase access to care. INVO is commercially advancing INVOcell through the opening of INVO Centers, opportunistically now pursuing acquisitions of established fertility (IVF) clinics in the U.S., and continuing to offer the technology to existing fertility practices.  Shares INVO closed at $.60.  The 52-wk range is $.3290 – $4.059.



    • On Nov. 30, INVO announced the birth of the first baby in Malaysia utilizing the INVOcell solution. The healthy baby boy weighed 3.53 kg and was born on November 11, 2022 at Tuanku Mizan Military Hospital in Kuala Lumpur. Physicians at Advanced Reproductive Centre (ARC), at Hospital Canselor Tuanku Muhriz (HCTM), at the National University of Malaysia conducted the IVC procedure. The patient was part of a prospective peer reviewed study of INVOcell compared to conventional IVF (“cIVF”) that took place at ARC at HCTM. The study, titled “Comparison of Treatment Outcomes among Sibling Oocytes Using Different Culture Systems—Conventional IVF versus INVOcell Device—And Evaluation of INVOcell User Satisfaction: The INVOcIVF Study,” was published in the International Journal of Environmental Research and Public Health. “We couldn’t be more pleased to have been a part of this family’s journey towards parenthood,” commented Steve Shum, CEO of INVO Bioscience. “The INVOcell solution is playing a key role in providing families across the world an alternative method to parenthood by leveraging its innovative medical device to allow fertilization and early embryo development to take place in vivo within the woman’s body; an approach that provides for affordable, high-quality, patient-centered fertility care.” Key findings of the study included:

      • The fertilization rate and good embryo quality were comparable (not significantly different) between INVOcell and cIVF.
      • Although both methods produce similar fertilization rates and good-quality embryos, the blastulation rates were better in the INVOcell group.
      • INVOcell can be used as an alternative method for reproductive treatment in carefully selected patients without jeopardizing outcomes.
      • cIVF is costly and not applicable in most rural and district areas, therefore, the INVOcell can be utilized as a cost-effective alternative to cIVF without sacrificing comfort and outcomes.
    • On Monday, November 14, INVO announced financial results for the third quarter ended September 30, 2022 and provided a business update. Revenue (excluding license revenue) was $235,321 compared to $40,303 in the third quarter of the prior year, an increase of 484% and up 61% sequentially compared to the second quarter of 2022. Clinic revenue increased to $176,395, or 370%, compared to the same period last year, and was up 57% sequentially compared to Q2 2022. All reported clinic revenue is derived from the Company’s Atlanta, Georgia-based INVO Center which is consolidated in the financial statements. Revenue from clinics, inclusive of both those accounted for as consolidated and under the equity method, was $450,131, an increase of 1,100% compared to last year and up 111% sequentially compared to the second quarter of 2022. Product sales increased to $58,926 during Q3 2022, an increase of 2,012% compared to the same quarter last year and were up 74% sequentially compared to the second quarter of 2022. INVO has completed due diligence on the previously announced fertility clinic acquisition target and is working to finalize definitive agreements..


    • On Nov. 10, Chinook provided a business update and reported financial results for the quarter and nine months ended September 30, 2022. “During the third quarter of 2022, we continued advancing our pipeline of clinical and preclinical programs for rare, severe chronic kidney diseases. We are pleased with the strong data presented at ASN Kidney Weekend 2022 from both our lead programs, atrasentan and BION-1301, in IgA nephropathy (IgAN), as well as from CHK-336 and our preclinical research approach,” said Eric Dobmeier, president and chief executive officer of Chinook Therapeutics. “We look forward to 2023, when we plan to initiate a phase 3 study of BION-1301 in patients with IgAN, present data from the ongoing phase 1 clinical trial of CHK-336 in healthy volunteers in the first half and report topline proteinuria data from the ongoing phase 3 ALIGN study of atrasentan in the third quarter.”



  • Borqs Technologies, Inc. (Nasdaq: BRQS, $.265), a global provider of 5G wireless solutions, Internet of Things (IoT) solutions, and innovative clean energy, recently provided the following updates on the Company.
  • On Dec. 8, Borqs announced its subsidiary, Holu Hou Energy (HHE), has received multiple purchase orders for its HoluPower xP solar energy storage systems for installation at homeowner locations in the Greater San Diego area in California. These orders represent the first for the Company in California. Whereas in Hawaii HHE works to develop and construct Single-Family Residential projects as an “end to end” provider, the Company will target the California homeowner market through already existing channel partners that will sell and construct the projects. For Multi-Dwelling Unit (MDU) Residential properties in the State, the Company will initially target apartment owners, REITs and other MDU stakeholders directly, then partner with existing licensed contractors for system construction. HHE has been focused on the Hawaii market since it began commercial shipments in 2020, in order to become successfully established in the largest market in the United States based upon solar installation penetration. Now it is turning to California, the largest market in terms of size of available opportunity. HHE recently completed the testing and documentation required for the HoluPower xP to be listed as an approved product by the California Energy Commission. The Company expects to be listed by early January 2023, after which permitting and installations can commence. In Hawaii, Holu Hou Energy has quickly become a leader for solar energy storage systems in the Single-Family Residential market, and has essentially created the previously untapped Multi-Dwelling Unit (“MDU”) Residential market for renewable energy by virtue of its “EnergyShare” technology. The same leading product attributes will benefit MDU property owners and homeowners in California. The potential available MDU market in California is believed to be in the billions of dollars. EnergyShare enables networked systems to share excess generation behind their respective utility meters, a game-changer for improving the project economics for the MDU market, including for low-income housing, rental property units and Home Owners Association managed condominiums and town homes. EnergyShare enables more energy to be delivered to load, and fewer batteries to be installed than the standard approach of a unit-by-unit installation.



Shares of InMed Pharmaceuticals Inc. (INM), a leader in the research, development and manufacturing of rare cannabinoids, closed at $2.03.




Thanks again for your attention this week. Please continue to share your thoughts, questions, & ideas as we move forward. 

In the meantime, please enjoy the balance of the weekly newsletter’s videos, quotes, updates and let’s find ways to crush it again this year!

Investing & Inspiration

  1. “By three methods we may learn wisdom: First, by reflection, which is noblest; Second, by imitation, which is easiest; and third by experience, which is the bitterest.” – Confucius
  2. “No man was ever wise by chance.” – Lucius Annaeus Seneca
  3. “Progress is man’s ability to complicate simplicity.” – Thor Heyerdahl
  4. “It is not in the stars to hold our destiny but in ourselves.” – William Shakespeare
  5. “It does not matter how slowly you go as long as you do not stop.” – Confucius

  6. “I want to put a ding in the universe.” – Steve Jobs

  7. “Research is creating new knowledge.” – Neil Armstrong

  8. “The reward for work well done is the opportunity to do more.” – Jonas Salk
  9. “Man is a creative retrospection of nature upon itself.” – Karl Wilhelm Friedrich Schlegel
  10. “There’s something about taking a plow and breaking new ground. It gives you energy.” – Ken Kesey
  11. “Success seems to be largely a matter of hanging on after others have let go.” – William Feather

  12. “The essential conditions of everything you do must be choice, love, passion.” – Nadia Boulanger
  13. “More business is lost every year through neglect than through any other cause.” – Rose Kennedy

  14. “Give me a lever long enough and a fulcrum on which to place it, and I shall move the world.” – Archimedes

  15. “A person who won’t read has no advantage over one who can’t read.” – Mark Twain
  16. “The best way out is always through.” – Robert Frost

  17. “Start by doing what’s necessary; then do what’s possible; and suddenly you are doing the impossible.” – Francis of Assisi
  18. “Without labor nothing prospers.” – Sophocles

  19. “Intellectuals solve problems, geniuses prevent them.” – Albert Einstein
  20. “This is the precept by which I have lived: Prepare for the worst; expect the best; and take what comes.” – Hannah Arendt

  21. “The best and most beautiful things in the world cannot be seen or even touched – they must be felt with the heart.” – Helen Keller

  22. “He who is brave is free.” – Lucius Annaeus Seneca
  23. “When something is important enough, you do it even if the odds are not in your favor.” – Elon Musk

  24. “I choose a block of marble and chop off whatever I don’t need.” – Auguste Rodin

  25. “Hope is the only bee that makes honey without flowers.” – Robert Green Ingersoll

  26. “He who knows that enough is enough will always have enough.” – Lao Tzu

  27. “Plans to protect air and water, wilderness and wildlife are in fact plans to protect man.” – Stewart Udall
  28. “In order to carry a positive action we must develop here a positive vision.” – Dalai Lama

  29. “A hero is someone who understands the responsibility that comes with his freedom.” – Bob Dylan
  30. “Inflation destroys savings, impedes planning, and discourages investment. That means less productivity and a lower standard of living.” – Kevin Brady
  31. “If we give something positive to others, it will return to us. If we give negative, that negativity will be returned.” – Allu Arjun
  32. “A good plan violently executed now is better than a perfect plan executed next week.” ~ George S. Patton
  33. “You must do the things you think you cannot do.”- Eleanor Roosevelt
  34. “Success is dependent on effort.” – Sophocles
  35. “Nobody who ever gave his best regretted it.” – George Halas
  36. “Lots of people want to ride with you in the limo, but what you want is someone who will take the bus with you when the limo breaks down.” ~ Oprah Winfrey
  37. “And when I breathed, my breath was lightning.” – Black Elk
  38. “Moderation is the silken string running through the pearl chain of all virtues.” – Joseph Hall
  39. “You are the sum total of everything you’ve ever seen, heard, eaten, smelled, been told, forgot – it’s all there. Everything influences each of us, and because of that I try to make sure that my experiences are positive.” – Maya Angelou
  40. “If you want a guarantee, buy a toaster.” – Clint Eastwood
  41. “We are an impossibility in an impossible universe.” – Ray Bradbury
  42. “If you think in terms of a year, plant a seed; if in terms of ten years, plant trees; if in terms of 100 years, teach the people.” – Confucius
  43. “I’d rather attempt to do something great and fail than to attempt to do nothing and succeed.” – Robert H. Schuller
  44. Do your little bit of good where you are; it’s those little bits of good put together that overwhelm the world.” Desmond Tutu
  45. “It takes considerable knowledge just to realize the extent of your own ignorance.” – Thomas Sowell
  46. “Do not dwell in the past, do not dream of the future, concentrate the mind on the present moment.” – Buddha”
  47. Surprise is the greatest gift which life can grant us.” –  Boris Pasternak
  48. “Trust in dreams, for in them is hidden the gate to eternity.” – Khalil Gibran 
  49. “Always be yourself, express yourself, have faith in yourself, do not go out and look for a successful personality and duplicate it.” – Bruce Lee
  50. “All life is an experiment. The more experiments you make the better.” – Ralph Waldo Emerson
  51. “There are no secrets to success. It is the result of preparation, hard work, and learning from failure.” –  Colin Powell
  52. “There is more to life than increasing its speed.” – Mahatma Gandhi
  53. “Your attitude is like a box of crayons that color your world. Constantly color your picture gray, and your picture will always be bleak. Try adding some bright colors to the picture by including humor, and your picture begins to lighten up.” – Allen Klein
  54. “Definiteness of purpose is the starting point of all achievement.” – W. Clement Stone
  55. “Success usually comes to those who are too busy to be looking for it.” – Henry David Thoreau
  56. “In matters of truth and justice, there is no difference between large and small problems, for issues concerning the treatment of people are all the same.” – Albert Einstein
  57. “Life is too short for long-term grudges.” – Elon Musk
  58. There cannot be a crisis next week. My schedule is already full.” – Henry Kissinger
  59. “Success consists of getting up just one more time than you fall.” – Oliver Goldsmith
  60. “The Earth is the cradle of humanity, but mankind cannot stay in the cradle forever.” – Konstantin Tsiolkovsky
  61. “Ours is a world of nuclear giants and ethical infants. We know more about war that we know about peace, more about killing that we know about living.” – Omar N. Bradley
  62. “Beauty surrounds us, but usually we need to be walking in a garden to know it.” – Rumi
  63. “But man is not made for defeat. A man can be destroyed but not defeated.” – Ernest Hemingway
  64. “Don’t watch the clock; do what it does. Keep going.” – Sam Levenson
  65. “Let there be work, bread, water and salt for all.” – Nelson Mandela
  66. “The social object of skilled investment should be to defeat the dark forces of time and ignorance which envelope our future.” – John Maynard Keynes
  67. “A successful society is characterized by a rising living standard for its population, increasing investment in factories and basic infrastructure, and the generation of additional surplus, which is invested in generating new discoveries in science and technology.” – Robert Trout
  68. “I know not with what weapons World War III will be fought, but World War IV will be fought with sticks and stones.” – Albert Einstein
  69. “It is the fight alone that pleases us, not the victory.” – Blaise Pascal
  70. “If you can’t describe what you are doing as a process, you don’t know what you’re doing.” – W. Edwards Deming
  71. “Never interrupt your enemy when he is making a mistake.” – Napoleon Bonaparte
  72. “Be sure you put your feet in the right place, then stand firm.” – Abraham Lincoln
  73. “Without investment there will not be growth, and without growth there will not be employment.” – Muhtar Kent
  74. “You have to do your own growing no matter how tall your grandfather was.” – Abraham Lincoln
  75. “Victory has a thousand fathers, but defeat is an orphan.” – John F. Kennedy
  76. “Delete the negative; accentuate the positive!” – Donna Karan
  77. “It’s crazy how fast time flies and how things progress.” – Nathan Chen
  78. “The world is a dangerous place to live; not because of the people who are evil, but because of the people who don’t do anything about it.” – Albert Einstein
  79. “Life isn’t about finding yourself. Life is about creating yourself.” – George Bernard Shaw
  80. “Everything has beauty, but not everyone sees it.” – Confucius
  81. A man must be big enough to admit his mistakes, smart enough to profit from them, and strong enough to correct them.” – John C. Maxwell
  82. “Walking with a friend in the dark is better than walking alone in the light.” – Helen Keller
  83. “A man who dares to waste one hour of time has not discovered the value of life.” – Charles Darwin
  84. “The greater danger for most of us lies not in setting our aim too high and falling short; but in setting our aim too low, and achieving our mark.” – Michelangelo
  85. “Progress is man’s ability to complicate simplicity.” – Thor Heyerdahl
  86. “I like to encourage people to realize that any action is a good action if it’s proactive and there is positive intent behind it.” – Michael J. Fox
  87. “Nothing is impossible, the word itself says ‘I’m possible’!” – Audrey Hepburn
  88. “But investment in space stimulates society, it stimulates it economically, it stimulates it intellectually, and it gives us all passion.” – Bill Nye
  89. “Bitcoin, in the short or even long term, may turn out be a good investment in the same way that anything that is rare can be considered valuable. Like baseball cards. Or a Picasso.” – Andrew Ross Sorkin
  90. “Life is a tragedy when seen in close-up, but a comedy in long-shot.” – Charlie Chaplin
  91. “No matter what you’re going through, there’s a light at the end of the tunnel and it may seem hard to get to it but you can do it and just keep working towards it and you’ll find the positive side of things.” – Demi Lovato
  92. “Infrastructure investment in science is an investment in jobs, in health, in economic growth and environmental solutions.” – Oren Etzioni
  93. “Educating our children and giving them the skills they need to compete in a global economy is a smart investment in our country’s future.” – Sheldon Whitehouse
  94. “Know thy self, know thy enemy. A thousand battles, a thousand victories.” – Sun Tzu
  95. “If one does not know to which port one is sailing, no wind is favorable.” – Lucius Annaeus Seneca
  96. “Beware of missing chances; otherwise it may be altogether too late some day.” – Franz Liszt
  97. “The sofa is a really important investment for anybody, and I don’t mean financially. You need to find a really great sofa that can transition with you, and you can build from there.” – Jeremiah Brent
  98. “There is no investment you can make which will pay you so well as the effort to scatter sunshine and good cheer through your establishment.” – Orison Swett Marden
  99. “Nothing in life is to be feared, it is only to be understood. Now is the time to understand more, so that we may fear less.” – Marie Curie
  100. “There is little that can withstand a man who can conquer himself.” – Louis XIV
  101. “In tennis, you strike a ball just after the rebound for the fastest return. It’s the same with investment.” – Masayoshi Son
  102. “A camel makes an elephant feel like a jet plane.” – Jackie Kennedy
  103. “The advance of technology is based on making it fit in so that you don’t really even notice it, so it’s part of everyday life.” – Bill Gates
  104. “Success depends upon previous preparation, and without such preparation there is sure to be failure.” – Confucius, Chinese 
  105. “Coming together is a beginning; keeping together is progress; working together is success.” – Edward Everett Hale
  106. “Never do anything against conscience even if the state demands it.”– Albert Einstein
  107. “Education is not only a ladder of opportunity, but it is also an investment in our future.” – Ed Markey
  108. “The true measure of a man is how he treats someone who can do him absolutely no good.” – Samuel Johnson
  109. “In my view, the biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital. Not only is the mere drop in stock prices not risk, but it is an opportunity. Where else do you look for cheap stocks?” – Li Lu
  110. “A successful society is characterized by a rising living standard for its population, increasing investment in factories and basic infrastructure, and the generation of additional surplus, which is invested in generating new discoveries in science and technology.” – Robert Trout
  111. “The best preparation for tomorrow is doing your best today.” – H. Jackson Brown, Jr.
  112. “Friendship marks a life even more deeply than love. Love risks degenerating into obsession, friendship is never anything but sharing.” – Elie Wiesel
  113. “Investing in women’s lives is an investment in sustainable development, in human rights, in future generations – and consequently in our own long-term national interests.” – Liya Kebede
  114. “Success isn’t measured by money or power or social rank. Success is measured by your discipline and inner peace.” – Mike Ditka
  115. “No matter how many goals you have achieved, you must set your sights on a higher one.” – Jessica Savitch 
  116. “Start where you are. Use what you have. Do what you can.”– Arthur Ashe
  117. “The secret of getting ahead is getting started.” – Mark Twain
  118. “The amount of work and the amount of both physical and emotional investment it takes to get to the top.” – Drew Bledsoe

Videos